Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New IPF drug passes early safety check in small trial

NCT ID NCT05895565

First seen Jan 07, 2026 · Last updated May 19, 2026 · Updated 21 times

Summary

This early-stage study tested a new drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects and lung function. This is not a cure, but a step toward finding better treatments to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IPF are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, 100029, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, 210008, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, 200030, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, 230000, China

  • Tongji Hospital Tongji Medical College of HUST

    Wuhan, Hubei, 430030, China

Conditions

Explore the condition pages connected to this study.